From the Food and Drug Administration.
Nightingale
S L
SL
D001088:Arabinonucleotides / Q000627:therapeutic use*; D001764:Blepharospasm / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000627:therapeutic use; D004345:Drug Industry; D005141:Eyelid Diseases / Q000188:drug therapy*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D009965:Orphan Drug Production; D013285:Strabismus / Q000188:drug therapy*; D013630:Tampons, Surgical / Q000592:standards*; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use*
D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate; D001905:Botulinum Toxins